Aduro BioTech, Inc., a clinical-stage immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. Its lead product candidate is CRS-207, an immuno-oncology therapy, which is in a Phase IIb clinical trial for the treatment of metastatic pancreatic cancer, unresectable malignant pleural mesothelioma, and ovarian cancer. The company also offers STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and develops monoclonal antibodies with the potential to yield immunotherapy. Aduro BioTech, Inc. also has a collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.